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ABSTRACT 
DUSTIN BUTTARS: A Comparison Between Estimated and Direct Measurements Of 
Oxygen Uptake In Breast Cancer Survivors 
(Under the direction of Dr. Claudio Battaglini) 
  
Purpose: This study compared maximal oxygen uptake (VO2max) between 
estimated and directly measured VO2max values obtained during a maximal cycle 
ergometer test in breast cancer survivors. Methods: Nine women (50 ±  6 years) 
diagnosed with early stage breast cancer (BCS) who had completed all primary cancer  
treatments within the past 3 to 6 months and nine age, weight, and fitness level matched 
women (59 ± 5),  with no history of cancer participated in the study. All subjects 
performed a VO2max test on an electronically-braked cycle ergometer. Using results of the 
test, an estimated VO2max was calculated, then compared to the directly measured VO2max 
obtained during the test using a dependent samples t-test. Results: Significant difference 
(p=0.01) was observed between directly measured (18.1± 2.7ml/kg/min) and estimated 
(16.3 ± 3.6ml/kg/min) VO2max values in BCS. Conclusion: Estimated VO2max calculated 
from a submaximal cycle ergometer test underestimates VO2max when compared to 
directly measured VO2max.
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Chapter I 
Introduction 
Breast cancer is the second most common form of diagnosed cancer and second 
leading cause of cancer death among women [American Cancer Society (ACS), 2013]. 
An estimated 234,580 new cases in the U.S. are expected in 2013 of which 40,030 are 
expected to die from the disease (ACS, 2013). Five-year survival rate for female breast 
cancer has increased from 63% in the 1960’s to 90% today (ACS, 2013). Survival 
however has come with a price. Treatments such as chemotherapy, hormone therapy, 
radiation and surgery each cause different side effects for cancer patients. Many of these 
side effects are treated with pharmacological interventions, however, the efficacy of 
pharmaceuticals may only provide temporary relief and long term effects of treatment 
may persist for years post completion of treatment.  
Recently, the medical community has given a great deal of attention to 
complementary non-pharmacological interventions that have proven to off-set or even 
reverse many of the side-effects commonly experienced by cancer patients during and 
after completion of cancer treatments. Among the different complementary interventions 
such as psychotherapy, dietary manipulations, stress management, and exercise; exercise 
is an intervention that has shown in cancer patients to positively affect many treatment-
related side effects (Battaglini et al., 2007, 2008; Burnham et al., 2002; Courneya et al., 
2003; Daley et al., 2007; Jones et al., 2008).  
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Current exercise guidelines for the breast cancer population recommend moderate 
to vigorous intensity activity, three to five days per week which mimic the age-
appropriate physical activity guidelines for Americans (Courneya et al., 2011; Irwin, 
2012; Schmitz et al., 2010; Thompson et al., 2010). Due to the beneficial effects exercise 
can have on treatment related side effects, it is imperative that exercise-testing guidelines 
be implemented to increase safety as well as to provide the most accurate information 
which is critical for the development of more precise exercise prescriptions.  
The integrative ability of the cardiopulmonary and skeletal muscle system, allows 
for the transport and utilization of oxygen by tissues for the production of energy. This is 
necessary for proper physiological function as well as to endure changes in energy 
expenditure necessary for the performance of activities of daily living as well as 
maintenance of health. Furthermore, cardiorespiratory fitness (CRF), commonly 
expressed as maximal oxygen uptake (VO2max) is considered the best cardiovascular 
fitness indicator  (Brooks et al., 2005) and has been inversely associated with all-cause 
mortality as well as cardiovascular disease deaths in a wide range of adult populations 
(Kavanagh et al., 2002, 2003). In breast cancer survivors, CRF is reduced by an average 
of 30% throughout the treatment process (Jones et al., 2011). The necessity of improving 
CRF in cancer patients cannot be overstated since higher CRF is associated with a 
significant reduction in breast cancer mortality (Holmes et al., 2005; Peel et al., 2009) 
and increases in overall quality of life (Burnham et al., 2003; Courneya et al., 2003; 
Daley et al., 2007; Herrero et al., 2006).  
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Research in the area of exercise testing and training for breast cancer patients is 
still young and underdeveloped. Jones et al., (2008) conducted a systematic review of the 
literature evaluating several methodological issues including (but not limited to) exercise 
testing paradigms and subject (patient) characteristics. It was concluded that the current 
literature is so broad in scope and methodology that methodological testing and 
prescription of exercise standardization among researchers is essential for the 
interpretation of the results of the studies examining the effects of exercise in cancer 
survivors.  
In cancer survivors, exercise testing most often involves the administration of 
submaximal cardiopulmonary protocols that estimate maximal oxygen uptake as well as 
maximal cardiopulmonary exercise tests (CPET) using treadmills and cycle ergometers 
(Jones et al., 2008). The result of CPET is not only used to evaluate the effects of 
exercise training on CRF, but is also used to establish training thresholds in the 
development of aerobic exercise prescriptions. Among the scientific community studying 
the effects of exercise in the cardiopulmonary system of cancer survivors, direct 
measures of CRF are considered the most accurate method of CRF evaluation. The 
results of maximal tests are usually reported as peak oxygen uptake (VO2peak) due to the 
inability of cancer patients to reach the pre-defined criteria for a maximal test. 
Furthermore, treadmill exercise testing offers its own set of limitations in the cancer 
survivor population due to many physical side effects derived from cancer treatments 
such as balance problems recently reported in the literature (Wampler et al., 2007; 
Winters-Stone et al., 2011). The negative impact of the treatment-related side effects, 
which often leads to reduction in physical activity and consequently decreases in overall 
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functionality, reduces cancer survivors exercise tolerability making it more difficult to 
perform maximal cardiopulmonary exercise tests. Also, the effects of cancer and 
treatment on pathophysiology may increase the risk of an adverse exercise-test related 
event (Jones et al., 2008). Not only do these safety hazards and physical limitations 
disallow the use of maximal exercise testing outside clinical settings due to the need of 
physician supervision, but also the accuracy of such tests administered in cancer 
survivors may be questionable. Often these tests are terminated prematurely due to 
muscle strength limitations and/or discomfort from equipment harnesses (mouth pieces or 
masks) used to collect gas exchange; factors not related to the true cardiopulmonary 
ability and the ability of the skeletal muscle system to uptake and use oxygen for energy 
production. In addition to these potential issues associated with the accuracy of maximal 
oxygen uptake testing protocols in cancer survivors, the results of the effects of exercise 
on CRF in cancer survivors even though promising, in regards to improvements that have 
been reported in the literature, have not been of similar magnitude to improvements seen 
in apparently healthy populations when matched by age, gender, and similar fitness 
condition. The smaller increases in VO2peak evaluated from direct measures raises the 
following questions; 1) Are the aerobic exercise prescriptions commonly administered, 
which include 3 times per week for approximately 30 minutes of moderate intensity 
(Jones et al., 2012), to cancer survivors not promoting the expected changes in CRF 
because they are not intense enough? 2) Are there cardiovascular or metabolic alterations 
due to cancer treatments that are not allowing for patients to experience the desirable 
changes in oxygen uptake with exercise training? 3) Or is it simply, the fact that exercise 
prescriptions devised from direct measures of VO2peak are not precise enough to elicit the 
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desirable changes in oxygen uptake efficiency due to the fact that these measurements 
may be underestimating the determination of training thresholds? In order for these 
questions to be answered, an initial evaluation on the potential differences in testing 
procedures needs to be addressed; for example comparing estimated, versus direct, 
measurements of VO2max in cancer survivors and the evaluation of the results to 
determine training thresholds for the prescription of the exercise training for cancer 
survivors is necessary. These evaluations are paramount in the quest to answering the 
interesting question regarding the small improvement in VO2ma seen in the exercise 
oncology literature.  
Statement of Purpose 
The purpose of this study was to compare the results of maximal oxygen uptake 
(VO2max) between estimated and directly measured VO2max values obtained during 
maximal cycle ergometer testing in breast cancer survivors. A secondary purpose was to 
compare training thresholds devised from estimated and direct measurements of VO2max, 
measured in watts, at 40%, 60%, 70%, and 80% of maximal oxygen uptake. 
Research Question 
RQ1: Will the estimated and direct measurements ofVO2max elicit similar maximal 
oxygen uptake values in breast cancer survivors? 
RQ2: Will training thresholds devised from estimated and direct measurement of 
maximal oxygen uptake in watts at 40%, 60%, 70%, and 80% of maximal oxygen 
uptake elicit similar values? 
 6 
 
Hypothesis 
H1: There will be a significantly higher maximal oxygen uptake (VO2max) 
estimated from a submaximal oxygen uptake exercise evaluation when compared 
with the directly measured maximal oxygen uptake test in a group of breast 
cancer survivors. 
H2: There will be a significant difference in watts at 40%, 60%, 70%, and 80% of 
VO2max devised from the estimated and directly measured maximal oxygen uptake 
testing evaluations, with higher wattage resulting at all percentages of VO2max 
from the estimated maximal oxygen uptake evaluation versus directly measured 
maximal oxygen uptake values.   
Definitions of Terms 
Breast Cancer Survivors: Early stage breast cancer patients who have completed major 
cancer treatment such as chemotherapy, radiation, surgery or a combination of these 
within the past 12 months. They may or may not be currently on hormonal therapy. 
Maximal Oxygen Consumption (VO2max): The maximum amount of oxygen consumed by 
an individual during an exercise test. Certain criteria must be decided upon before the test 
begins and must be met upon completion of the test to be considered a max. These 
criteria are: 1) A respiratory exchange ratio (RER) of >1.10, 2) A rating of perceived 
exertion (RPE) of >18, 3) Heart rate (HR) within 10 beats of age-predicted maximum, 4) 
A 150ml/min or less rise in VO2 with an increase in workload, or 5) An increase of 8 
mmol in lactate. Criteria are selected based on the design of the study and is usually 
determined by at least three of the criteria mentioned above being met to determine 
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whether the test was maximal. Should less than three criteria be met, the test is termed a 
peak test (VO2peak). A maximal test is considered the best measure of cardiovascular 
fitness (Brooks et al., 2005). 
Metabolic Equivalent (MET): A common expression of energy expenditure. One 
metabolic equivalent is equal to approximately 3.5 ml/kg/min of air consumed by an 
individual at rest (Brooks et al., 2005). 
Respiratory Exchange Ratio (RER): The ratio of oxygen consumed and carbon dioxide 
produced. An RER of 1.00 suggests 100% utilization of carbohydrates as the primary 
energy substrate, whereas an RER of 0.70 suggests predominant reliance on fats as the 
energy substrate. RER is not to be used solely as an indicator of substrate utilization due 
to the fact that metabolic conditions can artificially inflate the carbon dioxide (CO2) 
values (Brooks et al., 2005).  
Rating of Perceived Exertion (RPE): Currently, two RPE scales are widely used: the 
original or category scale, which rates exercise intensity on a scale of 6 to 20, and the 
category-ratio scale of 0 to 10. The RPE can be used as an indication of impending 
fatigue. Most apparently healthy subjects reach their subjective limit of fatigue at and 
RPE of 18 to 19 (very, very hard) on the category Borg scale or 9 to 10 (very, very 
strong) on the category-ratio scale; therefore, RPE can be used to monitor progress 
toward maximal exertion during exercise testing (Thompson et al., 2010). 
Assumptions 
1. All of the subjects followed the pre-test guidelines. 
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2. All of the subjects were honest in answering questions related to medical history, 
cancer history, and lifestyle evaluation. 
3. Every subject gave 100% effort on the maximal cardiopulmonary exercise test. 
Limitations 
1. The sample consists of only female breast cancer survivors therefore outcomes 
are not generalizable to other cancer types or male breast cancer survivors.  
2. A relatively small sample size.  
3. Despite all subjects being post-treated, it is possible those most recently finished 
with treatment (i.e.: within two weeks), may be experiencing more severe side 
effects thus potentially compromising their ability to perform the maximal 
cardiopulmonary exercise test.  
4. Previous testing experience may influence the performance of the breast cancer 
survivors on the maximal exercise test. 
5. Previous exercise history may skew the results.  
Delimitations 
1. The sample contained only female, breast cancer survivors. 
2. Only post-treated, early stages (I-III), breast cancer survivors were eligible. 
3. All subjects had undergone both chemotherapy and radiation as part of their major 
treatment plan. 
4. All subjects were no longer than 1 year post-treatment. 
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Significance of the Study 
 Cardiorespiratory fitness is commonly assessed using maximal exercise testing 
protocols (i.e., Cardiopulmonary Exercise Testing (CPET)). Measuring objectively 
cardiorespiratory fitness has gained significant attention in oncology patients due to the 
association between maximal oxygen uptake, cancer recurrence and mortality in patients 
with certain types of cancers. Furthermore, the result of a CPET is often used in exercise 
prescriptions for the determination of training thresholds for this patient population. A 
large number of cancer patients have difficulty performing even basic activities of daily 
living due to the deconditioned state they present during and after completion of cancer 
treatments; which is believed to be a result of the effects of cancer treatments themselves 
that lead to reduced physical activity and increased sedentary living. Therefore assuming 
cancer survivors would respond similarly to a maximal cardiopulmonary exercise test 
when compared to healthy counterparts, may produce different responses therefore 
compromising the ability of a precise interpretation of testing results commonly used for 
the evaluation of the efficacy of exercise training programs as well as for the 
determination of exercise prescriptions. A first step in improving the way aerobic 
exercise is currently prescribed to cancer patients is to identify tests that are more suitable 
for this population of cancer survivors. The fact that most survivors may not be able to 
perform well during a maximal cardiopulmonary test due to physical limitations that arise 
from cancer treatment or the discomfort of giving a maximal physical effort when 
experiencing severe fatigue, may influence the results of a maximal test thus raising the 
question whether a submaximal test can produce more meaningful results in the cancer 
survivor population. Also, due to the fact that most studies examining the effects of 
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cardiorespiratory function in cancer survivors have shown modest to low improvements 
in cardiorespiratory function after participating in an exercise training protocol, raises the 
question regarding the validity of using the results of a maximal test to devise training 
threshold in the cancer survivor population. Therefore, the first step in the quest of 
answering the question regarding the modest improvement in cardiopulmonary function 
in cancer survivors is to compare different testing protocols and then, if different results 
from these tests are in fact observed, implement exercise prescriptions using training 
thresholds devised from these tests so training responses can be compared. This study 
was designed to answer the first part of the question regarding potential differences in 
testing protocols and their influence in devising aerobic training thresholds in breast 
cancer survivors. The results of this initial study has the potential to serve as a starting 
point for future experiments that will be designed to improve current exercise training 
guidelines for breast cancer survivors.  
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Chapter II 
Literature Review 
This review is divided into five sections. Current breast cancer statistics are 
reviewed in section 1. The different breast cancer treatments commonly administered is 
discussed in section 2. Section 3 provides an overview of the physiologic impact cancer 
treatments cause to different physiological systems of survivors. Section 4 provides a 
summary of the exercise oncology literature. In section 5, the influence of 
cardiorespiratory fitness on cardiovascular and all-cause mortality is reviewed as well as 
the importance of cardiorespiratory fitness for cancer survivors. Lastly, section 6 
discusses the current literature on exercise testing in cancer patients.  
Section 1: Breast Cancer Statistics in the United States 
Among women, breast cancer is the second most common form of diagnosed 
cancer and second leading cause of cancer death [American Cancer Society, (ACS) 
2013]. Over 200,000 new cases in the U.S. are expected in 2013 of which nearly 40,000 
are expected to die from the disease (ACS, 2013). From 2005 to 2008 the incidence of 
breast cancer was 124 per 100,000 women and mortality for the same period was 23 per 
100,000 women (National Cancer Institute, 2013). New and more effective treatments 
and the decreased use of menopausal hormone therapy (MHT), or hormone replacement 
therapy, are partially to thank for reductions in death rate from the disease. However, 
with these new and improved treatments comes a multitude of side effects which cause 
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acute or chronic alterations in physiological functioning of the patient. Insults to the 
myocardium and skeletal muscular system, weight gain and fatigue are very impactful 
side effects that occur from the various cancer treatments. 
Section 2: Breast Cancer Treatments 
Chemotherapy 
Chemotherapy is a very common treatment used in breast cancer. Patients with all 
different stages of disease may need to undergo some form of chemotherapy. Many of 
these cause unwanted and debilitating side effects associated with reduced quality of life 
and physical function (ACS, 2013). Suppressed immune function, peripheral sensory 
neuropathy, nausea, decreased spatial awareness and balance, loss of muscle mass and 
function, loss of appetite, and psychological alterations such as fatigue, quality of life and 
motivation to perform daily activities are common side effects, but certainly not the full 
range (ACS, 2013; Shapiro et al., 1997). Chemotherapy is a broad class of treatment but 
is systemic in nature. Either intravenous or oral mode of treatment is used to target cancer 
cells throughout the body. Neoadjuvant chemotherapy is commonly used before surgery 
to shrink a solid tumor. Adjuvant therapy is often performed after surgery or radiation as 
insurance of killing any cancer cells that may have broken away from the original tumor 
site. Chemotherapy is usually given as a cocktail of numerous drugs each with different 
physiological killing specificity. It is given in cycles lasting weeks to months and the 
longer a treatment lasts, the more severe side effects can become. 
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Radiation 
Radiation poses its own set of challenges after treatment. Radiation is a targeted 
treatment in which the size of the tumor is reduced. Radiation can be implemented as 
either external beam or brachytherapy. External beam is the most common and uses high 
energy beams from a machine to directly target the tumor. Depending on the type and 
severity of the breast cancer, different lengths of treatment may be used. Longer radiation 
courses have stronger associations with causing cancer induced fatigue. Approximately 
70% of patients report experiencing some level of fatigue ranging from mild to 
debilitating (Courneya et al., 2003; Shapiro et al., 1997). Along with fatigue, radiation 
can cause pulmonary and cardiovascular injury in the form of fibrosis to the lung or 
pericarditis of the heart (Shapiro et al., 1997). Skin breakdown and possible loss of range 
of motion are quite common among patients treated with radiation. Lymphedema is 
another common side effect for breast cancer patients who receive surgery and then 
radiation. Lymphedema is evidenced by swelling of the limb associated with the side of 
treatment and in some cases can cause total incapacitation of the limb until the fluid is 
drained.  The cause of lymphedema is unknown and can manifest at any point during or 
after treatment. Radiation is a difficult treatment to undergo and the combination of 
chemotherapy and radiation can cause increased fatigue and exacerbation of side effects 
which ultimately has negative impacts on physical function and CRF of the patient 
(Irwin, 2012). 
Surgery 
Surgery is a typical treatment used for early stage breast cancers to fully remove 
the tumor. In breast cancer patients, surgery can incidentally cause inflammation at the 
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surgery site, chording of the axilla, and increased risk of lymphedema dependent upon 
the number of lymph nodes removed. Infection is another risk associated with surgery 
and can set the patient back even further. Surgery combined with radiation can increase 
the risk of lymphedema greatly, cause loss of range of motion around the affected limb 
and reduce muscular function. Psychologically, the patient may be apprehensive to use 
the affected limb, for fear of injuring it further, which has an effect on quality of life and 
overall physical function. 
Hormonal Therapy 
Hormonal therapy is a typically adjuvant treatment used in breast cancer to block 
the active hormones that breast cancer often targets, estrogen and progesterone. Cancers 
that are estrogen receptor positive are called ER positive breast cancers, where 
progesterone receptor positive cancers are PR positive. A few of the common hormone 
agents used are Tamoxifen, Femara and Aromasin. Each of these drugs works in slightly 
different ways but ultimately they reduce estrogen production in the body. These drugs 
reduce risk of cancer recurrence by about 40%, however many patients report side effects 
such as weight gain and hot flashes.  
Another hormone therapy drug used is Herceptin. Herceptin works by reducing 
the expression of Human Epidermal Growth Factor Receptor 2 (HER2/neu), a protein 
associated with more aggressive breast disease. A major side effect of this agent is 
cardiotoxicity, and thus cardiac function should be monitored (Irwin, 2012). Any exercise 
specialist working with patients taking Herceptin must understand the cardiac risks. 
Herceptin interferes with normal heart function by reducing the ejection fraction, similar 
to anthracycline treatment. 
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Section 3: Physiologic Impact of Treatment  
 The five year survival rate for breast cancer in women has increased from 63% in the 
1960’s to 90% in 2012 (ACS, 2013). This improvement however, comes with a price. 
Treatments such as chemotherapy, hormone therapy, radiation and surgery each produce 
different side effects for these survivors. An incomplete list of treatment related side 
effects is listed in Table 1. 
Many of these side effects have a 
compounding effect where the end result can 
be loss of skeletal muscle or atrophy from 
disuse along with even greater declines in 
cardiorespiratory fitness (CRF). These two 
issues are part of the proposed mechanisms 
behind cancer related fatigue. Fatigue is a 
very common side effect of cancer treatment 
and has been reported to affect 
                                                                        approximately 70% of all patients’ currently 
on or post treatment (Lucia et al., 2003; Shapiro et al., 2001). As fatigue grows more 
severe or starts to negatively impact the overall physical activity of the patient, physical 
inactivity begins to take hold. Skeletal muscle atrophy, reduced CRF, physical inactivity 
and age related physiologic declines all exacerbate the decline in quality of life and 
physical function of cancer patients. These, along with the impact each form of cancer 
treatment has directly on physical and physiological functioning, leads to an even greater 
Cancer Treatment Related Side 
Effects 
Myelosuppression 
Nausea 
Weight Gain 
Cardiac Toxicity 
Fatigue 
Decreased Strength 
Reduced Quality of Life 
Cognitive Dysfunction 
Reduced Cardiorespiratory Fitness 
Lymphedema 
Muscular Atrophy 
Hair Loss 
Peripheral Neuropathy 
Table 1: List adapted from Burnham et al., 
2002; Shapiro et al., 2001. 
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functional decline in this population. Jones et al. (2010) observed that VO2 peak in cancer 
patients consistently is 30% lower than matched sedentary individuals with no history of 
cancer. The exact cause of the poor VO2 peak is unclear but likely the result of normal 
age related physical decline, direct insult from treatment and indirect causes resulting 
from treatment such as reduced physical activity levels (Courneya et al., 2003; DeBacker 
et al., 2007; Jones et al., 2010). Reduced physical activity in even healthy adults leads to 
muscle atrophy and a loss of CRF, both of which have direct influences on the oxygen 
cascade.  
The oxygen cascade refers to the volume of oxygen (VO2) consumed through 
respiration from environmental air, its transport through the systemic vasculature and 
subsequent uptake at skeletal muscle that contributes to overall cardiorespiratory fitness. 
As either consumption or uptake declines from direct impact of treatment or 
deconditioning, the individuals VO2 decreases, elevating the risk of mortality. Certain 
chemotherapy agents, such as anthracyclines, can cause direct loss of compliance of 
cardiac tissue reducing left ventricular ejection fraction (LVEF) (Shapiro et al., 2001; 
Wonders et al., 2008). Reduced LVEF subsequently lowers the ability to supply adequate 
blood volume to skeletal muscle thereby reducing oxygen delivery. Heart rate and 
respiration therefore need to increase to keep up with oxygen demand causing the 
individuals cardiorespiratory system to become overworked quite possibly leading to 
increased fatigue (Dimeo 2001). Thus the oxygen cascade is further reduced in a vicious 
cycle. 
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Section 4: Summary of Exercise Oncology Literature 
 The field of exercise oncology is growing at an exponential pace. This may be 
due to the growing number of cancer survivor’s worldwide, increased survival rates due 
to better treatments and earlier diagnosis, and possibly a general shift in the attitude of 
oncologists to avoid inactivity during cancer. The past decade has seen a large number of 
exercise oncology studies compared to the previous two decades.  
A systematic review conducted by Jones, Pituskin and Battaglini (2012) identified 
56 exercise oncology studies from 1980 forward, in which efficacy outcomes for 
cardiorespiratory fitness were measured objectively and that did not include assessment 
of exercise in combination with other interventions. The researchers found that after the 
year 2000 to date, 51 studies fit the inclusion criteria, compared with only 5 between 
1980 and 2000. 91% of the qualified studies had been performed after the year 2000. The 
review also showed that 41% of the qualified studies examined the breast cancer 
population only and that 96% of the studies involved patients with curative disease 
compared to only 4% palliative. Furthermore, the review found that approximately 73% 
of the interventions were conducted in non-clinical settings, and nearly half of those did 
not include supervision. The outcome of this review confirms earlier reports that exercise 
seems to be safe with relatively few adverse events occurring within the cancer survivor 
population during exercise testing and interventions. Further, this review found that 
among the qualified studies the average measured VO2peak improved 2.3 ml/kg/min and 
the average estimated VO2peak improved 3.4 ml/kg/min. Although each of these increases 
was significant, they were still lower than the average 15% improvement in VO2peak 
among non-cancer clinical populations (Jones et al., 2012). Why is this so? Could it be 
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that current prescription methods in the cancer survivor population are inadequate to 
sufficiently stimulate the cardiovascular system for improvement? This study begins to 
answer that question.  
This provides some insight into the necessity of developing accurate and valid 
exercise testing protocols in the cancer survivor population. Of these, how many 
conducted identical VO2peak exercise testing? The answer to this question is beyond the 
scope of this study, but again confirms the reason for developing reliable and accurate 
exercise testing protocols that can be used repeatedly among the cancer survivor 
population for consistency both within and between studies.  
 The American College of Sports Medicine (ACSM) first developed exercise 
guidelines for cancer survivors in 2010 (Schmitz et al., 2010). The research group lead by 
Schmitz reviewed in depth the current literature and concluded with recommendations 
both generally and cancer-site specific for cancer patients such as breast, prostate and 
colon. In general, the recommendations were to ‘avoid inactivity’ and strive for the US 
Department of Health and Human Services (DHHS) Physical Activity Guidelines for 
Americans which are 150 min/week of moderate intensity physical activity or 75 
min/week of vigorous physical activity. Blanchard et al. (2008) found that nearly 70% of 
cancer patients report not meeting these guidelines prior to a cancer diagnosis. 
 The review covered six of the most commonly studied cancer sites, but for the 
purposes of this paper, only the data for breast cancer is presented. Due to the quantity of 
literature regarding specifically breast cancer studies, the authors had seven stringent 
criteria with which to include previous studies. After combing through the literature, 54 
breast cancer intervention studies were selected as eligible. Of these 54 studies, ‘all 
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surmised that exercise was safe’ before and during treatment for breast cancer. Only 28 
reported adverse events and the events were ‘rare, mild and expected on the basis of the 
activity prescribed’ such as plantar fasciitis from walking. One particular note the authors 
make is that 25% of participants in a home-based exercise intervention for shoulder 
rehabilitation had to discontinue due to symptoms or swelling. The recommendations 
conclude that exercise is both safe and feasible for breast cancer patients during and after 
primary treatment.   
 A total of 22 studies that assessed aerobic fitness were identified as eligible for 
the review. All but two of these found statistically significant improvements in aerobic 
fitness and as we know, higher cardiorespiratory fitness is associated with reduced all-
cause and cancer mortality (Gulati et al., 2003; Holmes et al., 2005; Myers et al., 2002; 
Peel et al, 2009; Sawada et al., 2003). Physical function was also measured in six 
randomized controlled trials using exercise as the intervention and all but two observed a 
statistically significant positive effect.  
 The review concludes that although there are specific risks associated with 
exercise for cancer survivors, there is consistent evidence that exercise during and after 
cancer treatment is safe (Schmitz et al., 2010).  
 A meta-analysis performed by Jones et al. (2011) reviewed numerous studies with 
the intention of examining the effect of exercise training on peak oxygen consumption in 
cancer patients. This meta-analysis however only accepted randomized controlled trials 
that contained supervised exercise training and that used a cardiopulmonary exercise test 
(CPET) with gas exchange analysis to assess cardiorespiratory fitness. The results 
returned six eligible studies involving a total of 571 adult cancer patients (exercise, 
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n=344; usual care, n=227). The pooled data indicate that exercise training significantly 
improved VO2peak approximately 2.90 ml/kg/min however again this is lower than the 
average increases seen with apparently healthy adults undergoing similar training 
volumes. The analysis concluded that there is no higher incidence of adverse events with 
exercise training, although safety was not rigorously monitored or reported during the 
reviewed studies. 
 Jones et al. (2011, 2012) and Schmitz et al. (2010) have concluded through their 
reviews that exercise is feasible and seems to be safe for cancer survivors; it can improve 
aerobic fitness with minimal adverse events and will generally improve physical function 
and quality of life in this population. The field of exercise oncology will continue to grow 
to include less studied cancer types, studies examining specific exercise responses, and as 
the results from larger prospective studies continue to mount, the accuracy of exercise 
prescriptions will improve in this population. 
Section 5: The Importance of Cardiorespiratory Fitness on All-Cause and Cancer 
Mortality  
Aerobic fitness is the number one parameter used to identify fitness level and all 
cause mortality among adults. Greater maximal VO2 is known to be associated with 
reduced risk of all cause mortality in both men and women (Gulati et al., 2003; Myers et 
al., 2002). Research groups found significant reductions in mortality for patients with 
exercise capacities above 5 Metabolic Equivalents (METS). Gulati’s group found a 17% 
reduction in mortality for each 1-MET increase in exercise capacity. Myers’ group found 
similar outcomes in that each 1-MET increase contributed an additional 12% reduction in 
mortality.  Peel et al. (2009) found an inverse relationship between cardiorespiratory 
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fitness and dying from breast cancer. Women with moderate fitness levels had a 33% 
lower risk of dying from the disease and women with the highest VO2’s had a 55% lower 
mortality risk. Sawada et al. (2003) found groups with the highest cardiorespiratory 
fitness had a 59% lower risk of cancer mortality compared to those with the lowest 
cardiorespiratory fitness. Cancer survivors may have a greater risk of declining aerobic 
fitness due to the negative consequences cancer treatment can elicit. Declines in physical 
function can manifest at the first treatment and continue years into recovery and can be 
markedly greater without exercise intervention. Exercise has been shown to mitigate 
many of the side effects seen with cancer treatment (Burnham et al., 2002; Courneya et 
al., 2003; Daley et al., 2007; Herrero et al., 2006; Ingram et al., 2007). Cancer 
rehabilitation programs and certified cancer exercise specialists are growing in number to 
deliver these exercise interventions, but standardized testing must be implemented to 
provide the most beneficial exercise prescription possible. 
Section 6: Oncology Exercise Testing 
The current literature regarding physical activity and cancer is growing. However 
the literature concerning exercise testing and cancer is sparse. Jones et al., (2008) 
contributed a systematic review of the literature concerning several types of exercise 
testing including submaximal and maximal, sample characteristics, end points and 
adverse event reporting. They concluded the current literature is so broad in scope and 
methods that standardization among researchers is essential. Intervention studies often 
used set-workload treadmill protocols, where most cardiopulmonary exercise testing 
(CPET) used a cycle ergometer and set-workloads. Jones et al. (2008) reported that most 
studies did maximal exercise testing and only 13 of 90 studies used age-predicted 
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submaximal exercise testing. Most CPET and intervention studies reported peak VO2 
while others reported submaximal training parameters. The research in this area has 
grown exponentially in the past decade but is far from developing standardized, safe 
guidelines for exercise testing and prescription. Due to the heterogeneity of the research 
involving exercise testing and cancer survivors, it is difficult to provide detailed 
guidelines for this population, thus the need to increase accessibility and standardize 
testing among cancer survivors.  
Disseminating the research reveals another strong reason for validating 
submaximal exercise testing standardization. Many maximal VO2 tests involving cancer 
patients end prematurely due to low self-motivation and/or poor physical function of the 
subjects. Peak testing requires a level of physical activity above and beyond what most 
cancer patients regularly perform. As previously mentioned nearly 70% of cancer patients 
reported not meeting the ACSM guidelines for physical activity prior to a cancer 
diagnosis. These patients do not have the physical capability to perform this level of 
intensive work nor do they feel comfortable doing it.  
Myelosuppression is a major concern from cancer treatment. Reduced 
hemoglobin levels cause anemia and possibly add to the fatigue many patients 
experience. Considering 70% of patients experience fatigue and may have chemotherapy 
induced anemia, pushing above and beyond daily activity is a foreign concept to them. It 
is quite likely they will be unable to give maximum effort, possibly another reason for 
reporting peak instead of maximal outcomes in the literature.  
 Despite the quantity of literature investigating exercise tolerance in cancer 
patients, only a few studies have directly examined the correlation between submaximal 
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and maximal exercise testing in cancer patients (De Backer et al., 2007; Jones et al., 
2006; May et al., 2010). May et al. (2010) found that submaximal testing did provide a 
reasonable alternative to exhaustive maximal testing in evaluating exercise intervention 
for a group of 147 cancer survivors. The mode of testing was on a cycle ergometer so the 
results cannot be compared to treadmill testing. However, May’s group found that only in 
the group of survivors whose HR peak reached 140 bpm or higher was moderately 
correlated (r=-0.51) with peak testing. The group who did not get to 140 bpm was only 
weakly correlated with peak outcomes. The take home point is that submaximal exercise 
testing provides a safe, inexpensive and generally well accepted form of exercise 
intervention evaluation for this population.  
De Backer’s group found that cycle ergometer submaximal exercise testing was 
moderately (r=0.71) correlated with maximal exercise testing, but they were more 
interested in a steep ramp test which proved to be slightly higher correlated with maximal 
exercise testing. A major limitation of this study was the lack of designated termination 
criteria for the maximal test. The researchers termed the test maximal when the subject 
reached exhaustion or could no longer maintain a predetermined cadence. This reiterates 
the point that maximal exercise tests are difficult to reliably obtain in this population. 
They are more often peak tests. Both May and De Backer agree that submaximal exercise 
testing needs to be validated for a variety of reasons. Submaximal tests are inexpensive, 
lower in risk to the subject, well received by cancer survivors and can be used to evaluate 
exercise intervention whereas maximal tests are used as more of a diagnostic tool in 
determining pulmonary or cardiac limitations requiring electrocardiogram (ECG) and 
physician presence.  
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In other clinical populations such as cardiac and pulmonary rehabilitation, 
submaximal exercise testing has shown moderate to high correlations with maximal 
exercise capacity (Cahalin et al., 1996; Guyatt et al., 1985; Riley et al., 1992; Thompson 
et al., 2010). This is promising considering the similar insults many cancer patients 
experience through treatment. Chemotherapy and radiation can cause cardiac and 
pulmonary implications as mentioned earlier. Either of these adverse impacts can directly 
influence dysfunction of the oxygen cascade leading to further CRF decline.   
 
Summary 
Cancer treatment poses a number of challenges to the cancer patient. Without 
experienced exercise specialists and cancer rehabilitation programs, exercise can pose 
quite a psychological burden to the patient. Cancer patients clearly have many more 
obstacles to overcome to initiate an exercise program than healthy adults, but the benefits 
may be of greater magnitude to this population. Barriers need to be removed to allow for 
quick exercise intervention among this group. Maximal testing poses a greater risk in 
already diseased populations, makes testing difficult in non-clinical settings and may 
cause psychological distress for the cancer patient. Although submaximal testing may 
over-predict VO2 max in apparently healthy populations, it may have benefit for diseased 
populations unable to give their best effort during an exercise test (De Backer et al., 
2007; May et al., 2010; Noonan et al., 2000). Submaximal testing can be performed in a 
non-clinical setting, does not require direct physician presence, and may give the patient 
more confidence in performing the test. Being able to accurately predict maximum VO2 
using submaximal protocols will open the door for more patients to participate in various 
 25 
 
exercise programs.  By creating evidence based standards from which to draw exercise 
prescriptions, the utilization of exercise in cancer rehabilitation will be safer and provide 
more reliable parameters leading to improved fitness and reduced cancer recurrence risk. 
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Chapter III 
Methodology 
 Subjects 
 Nine subjects in the breast cancer survivor group included women who were 
diagnosed with early stage (I-III) breast cancer, have completed all primary cancer 
treatment including surgery, radiation and chemotherapy within the past 3 to 6 months, 
and who were relatively sedentary (i.e., have not participated in regular exercise within 
the past year). Subjects in the breast cancer survivor group were recruited from the North 
Carolina Cancer Hospital on the campus of the University of North Carolina at Chapel 
Hill (UNC-CH). Subjects in the control group included nine women who did not have a 
history of cancer diagnosis or treatment, were relatively sedentary (i.e., had not 
participated in regular organized physical activity within the past year), and were healthy 
enough to participate in aerobic exercise. All attempts were made to match the control 
group with subjects in the breast cancer survivor group on both age and physical activity 
level. Subjects in the control were recruited from the faculty, staff, and student 
populations at UNC-Chapel Hill, as well as from the surrounding areas of the Triangle 
Region of North Carolina. 
 The inclusion criteria for participation in the breast cancer survivor group 
included: A confirmed diagnosis of early stage (I-III) invasive breast cancer, must have 
completed all major cancer treatments at least three months prior to participation in the 
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study, patients receiving adjuvant hormonal therapy or adjuvant trastuzumab were 
eligible, no presence of metastatic disease, female between the ages of 40 and 70 years of 
age, not involved in regular organized physical activity for at least 1 year prior to 
enrollment. The inclusion criteria for participation in the control group included: being a 
female between the ages of 40 and 70 years of age, no history of cancer diagnosis or 
treatment, did not regularly use anti-inflammatory medications, were either post-
menopausal or had not experienced a menstrual cycle for approximately one year and not 
involved in regular organized physical activity for at least one year prior to enrollment. 
 All subjects were required to complete a comprehensive medical questionnaire, a 
physical screening by either a physician or certified professional, and a 12-lead resting 
electrocardiogram (ECG).  
 
Instrumentation 
 A medical history questionnaire was used to record information about the subjects 
medical and cancer history including treatment type, physical activity level over the past 
year, age, race, and menopausal status. A portable stadiometer (Perspective Enterprises, 
Portage, MI) was used to measure height to the nearest 0.01 cm. A mechanical scale 
(Detecto, Webb City, MO) was used to measure body mass to the nearest 0.1 kg.  A GE 
Case Cardiosoft V. 6.6 ECG diagnostic system (General Electric, Palatine, IL) was used 
to assess cardiac function during rest and exercise. A Littman Stethoscope (3M, St. Paul, 
MN) was used to auscultate the heart and lungs during the physical screening, as well as 
for measurement of blood pressure during rest and exercise. A sphygmomanometer 
(American Diagnostics Corporation, Hauppage, NY) was used to measure blood pressure 
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during rest and exercise. A Lode electronically-braked cycle ergometer (Lode, Gronigen, 
The Netherlands) was used as the mode for the VO2peak test. Respiratory gas analysis and 
oxygen uptake (VO2) was measured using a Parvo Medics TrueMax 2400 Metabolic 
System (Parvo Medics, Salt Lake City, UT). A Polar telemetry system (Polar Electro Inc., 
Lake Success, NY) was used to measure heart rate. The rating of perceived exertion 
(RPE) was measured using Borg’s 6-20 Rate of Perceived Exertion (RPE) Scale. 
 
Research Design Overview 
This retrospective study used data collected from previous study IRB #11-1405 
conducted by Mrs. Elizatbeth Evans. Subjects were divided into two groups: a breast 
cancer survivor group and a control group which consisted of women with no history of 
cancer. Each subject visited the lab a total of three times (Orientation/familiarization, 
Visit 1 (VO2max test) and Visit 2 (collection of 24hr post exercise blood sample), however 
for this study, the procedures and data analyzed were collected during only the laboratory 
visit 1 (VO2max). All laboratory visits occurred in the Integrative Exercise Oncology 
Research Laboratory (IEORL) in the department of Exercise and Sport Science at UNC-
Chapel Hill. Approval from the Institutional Review Boards in the Department of 
Exercise and Sport Science, Lineberger Comprehensive Cancer Center, and the School of 
Medicine at UNC-CH were obtained before subject recruitment and testing. 
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General Procedures 
Orientation/ Familiarization Session 
All subjects underwent an orientation and familiarization session of the study 
protocol which was administered a few days prior to visit 1. Once all questions had been 
answered, each subject signed an informed consent. Each subject also completed a 
comprehensive medical and cancer history questionnaire, underwent a 12-lead ECG, and 
a physical examination performed by a physician or a member of the research team who 
was certified to perform physical exams. Further screening for exclusion was based on 
the criteria set forth by the ACSM as contraindications to exercise testing (Thompson et 
al., 2010).  
Upon clearance for participation in the study, several demographics were 
collected such as race, height, weight and age. Height and weight were collected using 
equipment in the IEORL. The comprehensive medical questionnaire was used to collect 
age, race, menopausal status, physical activity level and cancer treatment type. 
During the orientation subjects received in depth information about all the study 
protocols and participated in a familiarization of the study which included cycling with 
all the metabolic equipment set up for approximately 10 minutes. During the 
familiarization all adjustments to the equipment were recorded and reproduced during 
visit 1, the VO2max test day. This familiarization was conducted to get subjects used to the 
equipment and alleviate any anxiety or discomfort of being exposed to the equipment, 
which could influence the VO2max test.  During the orientation/familiarization visit to the 
laboratory, subjects were also provided with pre-assessment guidelines that included: to 
refrain from eating at least 2 hours prior to testing, refrain from exercise and caffeine at 
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least 12 hours prior, refrain from alcohol use at least 48 hours prior and to maintain 
adequate hydration, and were asked to follow those guidelines before reporting to the 
laboratory for the VO2max testing (visit 1). During laboratory visit 1, each subject 
performed a maximal oxygen consumption cycle ergometer test from which VO2max was 
obtained.  
 
Laboratory Visit 1: VO2max Test 
 During visit 1 to the IEORL, subjects received further explanation of the VO2max 
test protocol and were given the opportunity to ask any questions they might have at that 
time. After all questions were answered, all subjects underwent a VO2max test. Maximal 
oxygen uptake (VO2max) was determined using the Astrand Cycle Ergometer Maximal 
Test Protocol (Heyward, 2002). The VO2max test was performed on an electronically-
braked cycle ergometer. Subjects began by sitting quietly on the cycle ergometer for three 
minutes while resting metabolic data were collected. The first stage of the test was 
initiated and required the subject to cycle at 50 Watts for three minutes. The subjects 
were allowed to pedal at a comfortable cadence, as the resistance on the cycle-ergometer 
adjusted to maintain the set workload for each stage. At the end of the first stage, the 
workload was then increased by 25 Watts every three minutes until volitional fatigue. 
Heart rate, rating of perceived exertion (RPE), 12-lead ECG monitoring, and expired gas 
collection were performed throughout the test. Heart rate and RPE were recorded at the 
end of each minute. The subjects VO2max was determined as the highest VO2 recorded 
during the last stage of the protocol and the corresponding workload was also recorded as 
the subject’s peak workload. A cool down period was initiated upon completion of the 
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VO2max test and consisted of cycling at a very low workload (<20 Watts), while ECG and 
blood pressure were monitored continuously until they had returned to near baseline 
levels. 
 For the estimation of VO2max, data obtained during the VO2max test was used.  The 
Karvonen Formula for determining target heart rate was used to find 85% of heart rate 
reserve (HRR) and was calculated using the following equation: 85% HRR=(((220-age) –
RHR)*.85)+RHR. This 85% HRR calculation signals what would pertain to test 
termination during a submaximal exercise test and was used for the estimation of VO2max 
from the VO2max test. Estimated VO2max was then calculated after completion of the 
VO2max test using the last two consecutive stages in which steady state was reached with 
heart rates between 110 and 150 bpm.  The estimated VO2max was calculated using the 
American College of Sports Medicine equation as follows:  
VO2max = (2
nd
 VO2) + [((2
nd
 VO2 – 1
st
 VO2) / (2
nd
 HR – 1st HR)) x (HRmax – 2nd HR)]. 
Where:  
1
st
 VO2 = The VO2 measurement obtained in the second to last stage of the test in which a 
steady-state HR was reached within 110 to 150 bpm. 
2
nd
 VO2 = The VO2 measurement obtained in the last stage of the test in which a steady-
state HR was reached within 110 to 150 bpm. 
1
st
 HR = The HR obtained during the second to last stage of the test in which a steady-
state HR was reached within 110 to 150 bpm. 
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2
nd
 HR = The HR obtained during the last stage of the test in which a steady-state HR 
was reached within 110 to 150 bpm. This data point should be close to the previously 
calculated 85% HRR as possible. 
HRmax = The theoretical maximum of a person’s heart rate. It is calculated by using the 
equation: 220-age = x.  
 
Statistical Analysis 
All statistical analyses were performed using SPSS software version 20.0 for 
Windows. Statistical significance was set a priori at an alpha level of 0.05. Descriptive 
statistics, including means and standard deviations were calculated for demographic data 
and performance scores. 
Dependent samples t-tests were used to test for comparisons between the 
dependent variables of estimated and directly measured VO2max. Dependent samples t-
tests were also used to compare the estimated and measured wattages of 40%, 60%, 70% 
and 80% of VO2max.  The variables that were used to represent the wattage corresponding 
to 40%, 60%, 70%, and 80% of VO2max were calculated for both groups using a simple 
linear regression model (y = mx + B) shown in Figure 2.  
Exploratory analyses were conducted using the data of the control subjects. 
Specifically comparing estimated and measured VO2 outcomes with the breast cancer 
survivor group as well as comparing each of the training thresholds between groups. 
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Figure 1: Example regression model for determining workload 
corresponding to 60% of VO2peak. 
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Chapter IV 
Results 
 
 
The primary purpose of this study was to compare the results of maximal oxygen 
uptake (VO2max) between estimated and directly measured VO2max values obtained during 
maximal cycle ergometer testing in breast cancer survivors. A secondary purpose was to 
compare training thresholds devised from estimated and direct measurements of VO2max, 
using watts, at 40%, 60%, 70%, and 80% of maximal oxygen uptake. All data were 
entered into an electronic database for analysis.  All data were analyzed on SPSS version 
20.0 for Windows, a statistical software program. An alpha level of 0.05 was used for all 
statistical procedures, and descriptive statistics were presented in the form of means and 
standard deviations (SD). No statistical adjustments for performing multiple t-tests were 
made for the analyses of the data. Confidence intervals of the means are also provided, as 
well as an analysis of effect size for each statistical test. The effect size of each t-test 
analysis was computed via the Cohen’s d method (small effect size, d = .2 - .5: medium 
effect size, d = .5 - .8: large effect size, d  > .8). (Cohen, 1988). It should be noted that 
Cohen’s d is a method originally formulated for physiological research but has been used 
extensively within exercise science research to inform of physiological data as well. 
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Subjects 
This study included a total of 18 subjects, with 9 subjects in the breast cancer 
survivor group and 9 subjects in the control group. Physical characteristics for all subjects 
are presented in Table 2. Descriptive statistics are presented as mean ± standard deviation 
(SD).  
Table 2. Subject physical characteristics (mean ± SD) 
Characteristic Breast Cancer Survivor Group 
(n=9) 
Control Group 
(n=9) 
Age (years) 50 ± 6* 59 ± 5* 
Height (cm) 164.7 ± 5.8 163.8 ± 5.9 
Weight (kg) 76.9 ± 12.6 77.7 ± 13.3 
*p < 0.05 for comparing age between groups 
All subjects in the breast cancer survivor group received surgery, chemotherapy 
and radiation therapy as part of their major treatment and completed those treatments 
within 3 to 6 months prior to enrollment in the study. The breast cancer survivor group 
treatment characteristics are presented in Table 3.  
Table 3. Breast Cancer Survivors Treatment Characteristics 
Treatment Characteristic Number of subjects 
Surgery 9 
      Mastectomy  4 
      Lumpectomy 5 
*ACT 6 
ACT + Carboplatin 1 
Carboplatin + Taxotere 2 
Adjuvant Hormonal Therapy 6 
      Tamoxifen 5 
      Femara 1 
Adjuvant Trastuzumab 2 
*Combination of Adriamycin, Cytoxan and Taxol; Two subjects received additional 
medications concerning their cancer treatments, with one receiving Lapatinib and the 
other one Bevacizumab. 
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Descriptive statistics for VO2 and workload and training thresholds devised from 
direct and estimated VO2 measurements for all subjects are presented in Table 4.  
Table 4. Measured and estimated VO2 and training thresholds (mean ± SD). 
 Breast Cancer Survivor 
Group 
(BCS) 
Control Group 
(CNT) 
Measured VO2peak 
(ml/kg/min) 
18.13 ± 2.7* 18.51 ± 5.1 
Estimated VO2max 
(ml/kg/min) 
16.36 ± 3.6* 18.80 ± 6.1 
Measured 40% Watts 25 ± 33 37 ± 43 
Estimated 40% Watts 18 ± 31 38 ± 41 
Measured 60% Watts 57 ± 23 68 ± 35 
Estimated 60% Watts 48 ± 18 70 ± 31 
Measured 70% Watts 73 ± 19
# 
84 ± 32 
Estimated 70% Watts 63 ± 12
#
^ 85 ± 27^ 
Measured 80% Watts 90 ± 17 99 ± 30 
Estimated 80% Watts 77 ± 9^ 101 ± 23^ 
*Significant difference between MVO2peak and EVO2max in BCS group (p<0.05). 
#Significant difference between M70% and E70% in BCS group (p<0.05). 
^Significant difference between BCS and CNT groups at both E70% and E80% (p<0.05). 
 
Hypothesis 1, there will be a significantly higher maximal oxygen uptake 
(VO2max) estimated from a submaximal oxygen uptake exercise evaluation when 
compared with the directly measured maximal oxygen uptake test in a group of breast 
cancer survivors, was measured using a dependent samples t-test. The mean predicted 
and measured VO2max values were used in the analysis. Significant differences were 
found between the directly measured and estimated VO2 values in breast cancer survivors 
(18.1± 2.7 ml/kg/min, 16.3 ± 3.6 ml/kg/min, respectively, p=0.01, Effect size (Cohen’s d) 
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=0.56, and 95% of CI of mean lower = .25, upper = 3.30). No significant differences 
were observed between direct and estimated measurements in the control group. 
Hypothesis 2, there will be a significant difference in training thresholds 
expressed in watts at 40%, 60%, 70%, and 80% of VO2max devised from the directly 
measured and estimated maximal oxygen uptake testing evaluations, with higher wattage 
resulting at all percentages of VO2max from the estimated maximal oxygen uptake 
evaluation versus directly measured maximal oxygen uptake values, was measured using 
4 dependent samples t-tests. The mean wattage values at each percentage of VO2max were 
used in the analysis. The results of the analyses of hypothesis 2 are presented in Table 5. 
Table 5. Results of the Analyses of Hypothesis 2 
Training 
Thresholds 
(Watts at 
% VO2max) 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Effect 
Size 
(Cohen’s 
d) 
T df Sig.  
Lower Upper 
40% 
VO2max  
3.17 -2.553 12.108 0.15 1.50 8 0.08 
60% 
VO2max 
4.72 -3.558 18.224 0.37 1.55 8 0.07 
70% 
VO2max 
5.15 -1.003 22.781 0.70 2.11 8 0.03 
80% 
VO2max 
6.36 -4.999 24.332 0.67 1.52 8 0.08 
* Significant difference between directly measured and estimated training thresholds at 
70% of VO2max. 
No significant differences were found between the directly measured and 
estimated training threshold in watts at 40%, 60%, and 80% of VO2max in the breast 
cancer survivor group analyzed in the study. At 70% of VO2max significant difference in 
the determination of training threshold expressed in watts devised from directly measured 
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vs. estimated VO2max was observed (73.4 ± 19 Watts, 62.5 ± 12 Watts, p=0.03 
respectively).  
No significant differences were found between estimated and directly measured 
training thresholds devised from watts within the control group (p>0.05 within each 
training threshold).  
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Chapter V 
Discussion 
 
Review 
A systematic review conducted by Jones et al., (2008) revealed that most studies 
in the field of exercise oncology conducted maximal exercise testing, as well as age-
predicted submaximal exercise testing, for the assessment of cardiopulmonary function. 
The review further identifies the different methods, termination endpoints, reporting of 
outcomes and differences in testing used in exercise oncology research. The final 
conclusion from Jones’s systematic review is that the current guidelines for oncology 
exercise testing vary too greatly between studies to make many evidence-based 
recommendations at this time other than maximal exercise testing for the assessment of 
cardiorespiratory function is feasible and safe to perform in oncology patients. Many 
questions concerning exercise testing in cancer survivors still exist. For example; how do 
the insults that occur from treatment affect the outcome of oxygen uptake capacity and its 
influence on the design of exercise prescriptions in oncology patients? Are the current 
prescription techniques accurately stimulating an optimum training response that 
maximizes improvements in maximal oxygen uptake in oncology patients? Many cancer 
patients have difficulty in performing any level of exercise due to the cancer treatment 
related side effects, fatigue and other physiological alterations that occur such as reduced 
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oxygen carrying capacity and decreased muscular strength (Irwin 2012). Asking them to 
perform a maximal exercise test may not yield the best results due to their reduced 
cardiopulmonary, muscular, or both, capacities in performing such tests. A possible 
alternative may be performing a submaximal exercise test where VO2max is estimated. 
Cancer patients may be more prone and able to perform such tests,  require less 
equipment, is less time consuming, does not require medical personnel on site, and it is 
more applicable to gyms and clinics that may not possesses the capability to run maximal 
cardiopulmonary exercise tests.   
Current research in the field of oncology exercise testing is quite minimal. Only a 
few studies have been conducted and none, to our knowledge, directly examined the 
difference between submaximal and maximal aerobic exercise testing in cancer survivors 
with the exact same protocol. Previous studies have compared different cycle ergometer 
maximal exercise testing protocols from the one used in the current study (DeBacker et 
al., 2007; May et al., 2010). The results of those studies found that submaximal exercise 
testing was weakly to moderately correlated with maximal exercise testing. 
Therefore the purpose of this study was to examine whether submaximal and 
maximal cardiopulmonary testing protocols elicit similar results in breast cancer 
survivors who suffer physiological alterations as a result of having and receiving 
treatment for cancer. More specifically, this study compared the results of maximal 
oxygen uptake (VO2max) between estimated and directly measured VO2max values 
obtained during maximal cycle ergometer testing in breast cancer survivors. A secondary 
purpose was to compare training thresholds devised from estimated and direct 
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measurements of VO2max, measured in watts, at 40%, 60%, 70%, and 80% of maximal 
oxygen uptake. 
Aerobic capacity outcomes in breast cancer survivors 
The current study found that estimated VO2max was significantly lower than 
measured VO2peak in a group of post-treated breast cancer survivors. The results were 
somewhat surprising considering that in healthy, non-clinical population’s submaximal 
exercise testing typically overestimates VO2max (Thompson, 2010). Earlier studies using 
cancer survivors have found weak to moderate correlation between submaximal and 
maximal cycle ergometer testing however those studies used different exercise protocols 
than the current study and were designed to assess an intervention outcome (DeBacker et 
al., 2007; May et al., 2010). In the study by May et al., (2010) there was a caveat that the 
subject needed to obtain a heart rate of at least 140 bpm in order to be included in the 
correlational analyses between submaximal and maximal exercise testing. May’s group 
used the 140 bpm threshold because in healthy subjects Astrand and Rodahl 
recommended a heart rate up to or above 140 bpm to generate the best estimate of aerobic 
capacity (May et al., 2010).  Psychological and emotional influences such as test anxiety, 
fear, or excitement, may cause a marked elevation in submaximal heart rate without 
either VO2peak or performance being affected (Burnham et al., 2002). The initial theory 
was that submaximal testing would overestimate VO2max even more so in this population 
compared with healthy controls. Common functional barriers found in the breast cancer 
population who have received treatment for cancer include reduced physical fitness, 
reduced cardiopulmonary capacity and muscular weakness would contribute to the 
inability of the survivors to reach true maximal exertion, defined previously, on a 
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maximal aerobic capacity exercise test (Courneya et al., 2003, 2011; Irwin 2012). The 
early test-termination that would result, thus determined as VO2peak, would correspond 
with lower than maximal heart rate responses giving the impression the individual is 
more physically fit thus inflating the estimated VO2max outcomes. Another possible 
explanation for the underestimation of VO2max in the breast cancer survivors in this study 
could be attributed to large heart rate variations in response to exercise observed during 
testing. In this population we have seen large day-to-day heart rate variations and 
considerable elevated resting heart rates when compared to age-matched healthy, 
sedentary control subjects, likely due to the cancer treatments and reduced fitness level. 
Cardiotoxic chemotherapy agents, reduced physical activity, muscle atrophy and 
sarcopenia would all play a role in reducing aerobic energy system utilization or 
interference with the normal oxygen cascade that is directly responsible for determining 
aerobic capacity outcomes (Irwin 2012; Jones et al., 2011; Shapiro et al., 2001). At some 
point during their treatment, they were likely exposed to an agent that has direct cardiac 
side effects such as reducing ejection fraction, or indirectly through reduced physical 
activity leading to further functional decline.  
The nature of the mode and test protocol in this experiment could have also 
implicated the surprising results of this study. As fitness level and muscular strength and 
endurance decline through the cancer experience, the ability to power the pedals on a 
cycle ergometer will inevitably decline as well. Since cycle ergometry is a more localized 
mode of exercise, using primarily the lower limbs, a quicker localized muscular fatigue 
could contribute to a premature termination of the test by some of the breast cancer 
survivors during the study. This limitation would reduce the ability of the subjects to 
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perform maximally on a cycle ergometer test, which appeared to be the case in some of 
the tests performed during the study. Quite a few of the breast cancer survivors during the 
study terminated their cardiopulmonary tests because of their inability to pedal at a higher 
wattage (lack of strength to power the pedals), and not because their heart rates or oxygen 
uptake had reached their potential maximal capacities. This is all speculation at this time, 
however, due to the fact that the increase in heart rate observed from the initial stage of 
the test to the subsequent stages of the protocol appeared to be much greater in the BCS 
group when compared to the control group; a factor that could influence the regression 
model used for the estimation of VO2max. Therefore, it is recommended that this study be 
reproduced using treadmill protocols to see if the localized nature of the cycler ergometer 
test may have influenced the results of this current study. Despite the localized fatigue 
limitation that may have occurred using cycle ergometry, this mode of testing is still 
preferred because of the balance and peripheral neuropathy that is common among cancer 
patients (Irwin 2012). Cycle ergometry provides a reasonably safe alternative in testing 
patients who may experience the aforementioned side effects. 
Another factor that was observed during the current study that may have 
influenced the results was that some breast cancer survivors experienced hot flashes 
during testing, which could have altered their heart rate response during the test and 
consequently the estimation of VO2max, since heart rate is a major variable in the 
prediction of the maximal oxygen uptake value. Since hot flashes are a common side-
effect from cancer treatments, this increase in temperature during test can alter heart rate 
response significantly, which could partly explain some of the surprising elevated jumps 
in heart rate observed for some subjects when moving through some stages of the 
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maximal test. For these subjects, re-scheduling of the test should be considered for future 
trials comparing the results of maximal oxygen uptake evaluation using directly 
measured and estimated testing protocols.  
When the study was initially designed the criteria for termination of the 
submaximal exercise test was 85% of heart rate reserve (HRR), Due to the nature of this 
retrospective study, and after evaluating the data obtained for analyses, it was noted that 
several subjects in the BCS group did not reach 85% HRR during the maximal oxygen 
uptake test, thus the VO2max estimations were calculated using an exercise termination of 
75% HRR. Likewise, four of the sedentary controls were unable to reach even 75% HRR 
which became a major limitation of this study. This modification itself points to the 
possibility of a larger problem within the cancer population, regarding the precision of 
exercise prescriptions devised from cardiopulmonary exercise testing protocols, posing 
interesting questions such as: are the current testing techniques, which are mostly based 
on healthy adults, appropriate for cancer patients? Do the current length of stages to reach 
steady-state heart rate (HR) and the workload increases allow those with heart rate 
variations and physiological alterations affecting the oxygen cascade allow for a true 
steady-state HR to be reached? Many of the subjects in the study did not reach a steady-
state HR on the last stage of the test used for the estimation of VO2max, despite finishing 
the stage; also, as previously mentioned, the jump in HR was significantly greater than 
expected considering the relatively low 25 Watts increase between workloads. Longer 
stages or smaller increases in workload may be considered when designing specific 
cardiorespiratory exercise testing for cancer patients. The current study used 25 Watts 
increases between workloads and three minutes per stage. Using 15 Watts increases and 
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allowing for 3 to 5 minute stage lengths might allow for steady-state HR to be reached 
and a better prediction of maximal oxygen uptake. 
Another potential limitation that could have impacted the results of the study was 
the nature of the assessment of maximal oxygen uptake using a metabolic system. Many 
of the breast cancer survivors felt overwhelmed with the mask during the test. Even 
though a familiarization session was used to get subject used to the equipment, most of 
them felt that the mask made them feel too hot and they would rather have participated in 
the test without having to use it. Most likely, the combination of the effort along with the 
discomfort of using the mask could have also influenced the results. 
The average VO2peak found in the breast cancer group was 18.13 ml/kg/min which 
is considered very poor for healthy adult females 70 to 79 years old (Thompson et al., 
2010). The greatest VO2peak found in this group was 21.3 ml/kg/min and is still 
considered poor in the 70 to 79 age classification. The Modified Bruce Treadmill 
Exercise Test was developed for diagnosis of coronary risk patients whose aerobic 
capacity was severely diminished (Noonan et al., 2000). The same guidelines should 
correspond to cancer patients whose aerobic capacity is considered below average or 
worse. Currently, many studies and programs around the country use the Modified Bruce 
Treadmill Test, but unfortunately due to balance issues and peripheral neuropathy which 
are very common side effects of cancer treatment, not all patients can safely or fully 
perform a treadmill exercise test. Developing a standardized cycle ergometer protocol 
with longer stages and/or smaller increments in workload for the patients who are of 
lower physical function may prove more appropriate. Regardless of which method of 
exercise testing is used, the consideration for the standard error of measurement of any 
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metabolic system should be realized. The metabolic system used in this study has a 
standard error of approximately +/- 2% which could influence the results of future testing 
where power is inadequate or differences in the means are just significant.  
 Despite numerous studies citing the safety of maximal exercise testing in cancer 
patients (Irwin 2012; Jones et al., 2006, 2008, 2012), there is still a psychological barrier 
many of these patients have in performing maximally during a test or during general 
exercise. As a professional who has worked with many cancer patients, I have observed 
that motivation to push past a certain limit is lacking in this population due to the fear of 
injury or other negative consequences. Not all patients respond this way and in fact many, 
whose cardiorespiratory fitness is above average, may be able to perform a true maximal 
exercise test. 
 The current study found four of the nine breast cancer subjects, and only three of 
the sedentary controls reached maximal termination criteria defined as: 1) A respiratory 
exchange ratio (RER) of >1.10, 2) A rating of perceived exertion (RPE) of >18, 3) Peak 
heart rate (HR) within 10 beats of age-estimated maximum, 4) A 150 ml/min or less rise 
in VO2 with an increase in workload. Lactate reading was excluded from this list as it 
was not taken during the study. Because only four termination criteria points were set, in 
order to be termed a maximal test, at least three must have been reached. The four breast 
cancer subjects and three sedentary controls that reached maximum were also the only 
subjects who obtained at least 125 Watts during the cycle ergometer exercise test. This 
might suggest that a certain level of fitness may be needed to even consider performing a 
maximal test or it could point to a physiological difference between the two subsets 
(<125 Watts and >125 Watts) that was either present before the test or developed as a 
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result of undergoing a different type of cancer treatment. Is it possible those who reached 
maximum did not undergo cardiotoxic therapy or was there another difference in type, 
length or combination of treatment that contributed to the better response to the maximal 
cardiopulmonary exercise test in the breast cancer group? A follow up study could 
analyze this question further. 
In the control group no significant difference was found between estimated 
VO2max and measured VO2peak (p=0.87), however when the data for the subjects who did 
not reach 75% HRR is excluded (3/9), the remaining six data points found statistical 
significance and is nearly identical to the results of the breast cancer group where 
estimated VO2max is significantly lower than measured VO2peak (p=0.03). This again 
suggests that either a certain level of physical function is needed to obtain an accurate 
VO2max using this particular protocol for this particular group of deconditioned subjects 
or that modifications to this protocol would allow for a more accurate aerobic capacity 
outcome, such as longer stages or smaller increases in workload between stages.  
Using submaximal exercise testing to estimate VO2max in early stage breast cancer 
survivors who had completed major cancer treatment between 3 and 6 months may not be 
the most appropriate method based on the results of this study. If estimated VO2max is 
lower than actual VO2peak and prescriptions are then developed using the estimated value, 
workloads will be under-represented, for example: 60% VO2max might correspond to a 
lower actual workload of maybe 50% VO2peak. This could possibly be one of the reasons 
for the less than 1 MET increases in aerobic capacity that are usually observed in cancer 
patients after aerobic training interventions of 12 to 16 weeks (Jones et al., 2012). 
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Aerobic training thresholds in breast cancer survivors 
 The secondary purpose of the study was to examine whether workloads expressed 
in watts as a percentage of measured VO2peak were different from workloads at identical 
percentages calculated from estimated VO2max. The wattage at 40%, 60%, and 80% were 
not significantly different between the estimated VO2max and measured VO2peak (p=0.08, 
0.07, and 0.08, respectively); however significant difference was observed at the wattage 
devised from 70% estimated VO2peak vs. measured VO2max (p=0.03). It is quite possible 
that using a larger sample size would produce statistical significance among the other 
percentages. The trend toward significance and the small effect size of the analyses 
suggests that the analyses were underpowered when evaluating the differences in the 
determination of training thresholds at 40%, 60% and 80% of VO2max where the standard 
deviations are even larger than the mean. However, at 70% of VO2max, the moderate to 
high effect size (d=0.70), with smaller standard deviations, showed significantly different 
training thresholds. When further examining the data, and results of the analyses, besides 
the small sample size and large standard deviations at 40% and 60% of VO2max, the heart 
rate response of the cancer patients during the first stages of the test, may also help 
explain the non-significant difference between the training thresholds devised using the 
results of the directly measured and estimated VO2max values. 
 The raw data from this study show that during the first stage of each cycle 
ergometer test, the breast cancer survivors’ heart rates remained relatively stable, 
however at the second and third stages when a load of 25 Watts was added for each stage, 
there was a large jump in heart rate for many of the subjects compared with the relatively 
small increase of 25 Watts when compared to the control group. This suggests that the 
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workload increase was quite significant for the subjects and the relative intensity was 
such that the subjects did not have the lower limb strength to adjust to the new workload 
easily. These large jumps in heart rate, due to the lower limb strain, produce a sharp 
divergent point on the regression line where maximal exertion or fatigue will set in 
sooner, compared with oxygen uptake. The data also show that less than half of the 
subjects reached true maximal exertion and when the VO2 data is evaluated, we notice 
that only two of the subjects who reached maximal exertion actually had a plateau in 
VO2. This again suggests that the workloads used for this population either begin at too 
high of an intensity or the change in watts between stages is too great to allow for a 
comparable heart rate response compared with oxygen uptake. As the workload increases 
the subjects are unable to sustain the increased muscular demand due to reduced lower 
limb strength, a possible reduction in the oxygen cascade where oxygen uptake within the 
muscle is altered, test anxiety, and discomfort with the metabolic equipment on their face. 
A familiarization session was conducted to reduce the effects of test anxiety and 
discomfort, but an adjustment to the actual test protocol may help to eliminate the issue 
of reduced lower limb strength.  
 Not all breast cancer survivors respond the same way to an exercise test. 
Differential treatments, stage of cancer, previous physical activity levels, age, and body 
composition will vary between patients and thus will likely have an impact on the ability 
of the survivor to perform the exercise test.  
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Conclusions 
 The results of this study suggest that using a cycle ergometer testing protocol for 
the estimation of VO2max in breast cancer survivors may underestimate maximal oxygen 
uptake, and therefore, training thresholds devised from submaximal tests should be 
evaluated with caution. Further, the administration of maximal oxygen uptake tests in this 
specific population utilizing cycle ergometry may be negatively influenced due to the 
localized lower limb muscular fatigue that is quite common among breast cancer 
survivors who have undergone treatment for cancer.  
 
Recommendations for future research 
 Many of the subjects in this study were unable to reach 85% HRR. A lower 
submaximal termination endpoint may need to be used. Due to the inability of many 
subjects to reach the predetermined end point, it is possible that in the subjects mind there 
may be little to no difference between terminating the test at 85% HRR or maximal 
exertion. If the field of exercise oncology would like to continue utilizing cycle 
ergometer exercise testing for fitness classification or for the evaluation of interventions, 
modifications to the current submaximal testing procedures may need to be developed for 
breast cancer survivors, such as lowering the test termination criteria of HR threshold, or 
increasing length of stages, and/or decreasing the amount of change between stages to 
allow for a steady-state HR to be reached. These changes may also allow for more 
subjects to reach defined maximal exertion on cycle ergometer testing due to the ability 
to pedal for longer durations before lower limb fatigue sets in. As not all subjects reached 
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85% HRR, less than half of the subjects reached true max, as defined earlier, in this 
study.  
 Future studies should also evaluate a larger sample size and ensure the study is 
properly powered and to allow for perhaps examination of the stratification of the sample 
based on age, different cancer treatments patients underwent, and also the physical 
activity level prior to testing. All of these factors could influence the results of the 
maximal oxygen uptake evaluation in this population. 
 Comparing these results with similar findings using a treadmill exercise protocol 
would be another great recommendation. By utilizing a treadmill test for exploration 
between estimated and directly measured maximal oxygen uptake, we may find different 
results, due to walking being a more natural exercise, which might then suggest that 
unless the subject is a trained cyclist, using a cycle ergometer protocol is inadequate in 
the breast cancer population.  Further, using the same cycle ergometer protocol and then 
lower limb strength training the subjects between maximal oxygen uptake tests would 
also help to identify whether the lower limb strength is truly a limitation of this particular 
protocol.  
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